Silexion Therapeutics (SLXN) - התחייבויות לטווח ארוך להון

Silexion Therapeutics Corp (SLXN) is implementing advanced RNA therapy methods to curb tumor growth, creating personalized treatment protocols for severe pathologies. Business efficiency relies on the trial results of pancreatic cancer drugs under a moderate risk level, while the individual long-term debt metric stands at 5.74. This chart of stock quotes on GURU.Markets complements data regarding the company's laboratory partnerships and patent buyout strategy.

Silexion Therapeutics Corp (SLXN) specializes in developing oncological RNA platforms with stringent cold-chain logistics requirements. This ratio measures the business's dependence on long-term borrowings relative to the market value of equity. By analyzing the history of long-term debt leverage, an investor can observe the balance between credit load and capitalization. A decrease in this metric confirms the funding stability of high-tech supply chains, allowing for an assessment of asset overheating risks or hidden undervaluation potential.